Gilead Sciences (GILD) is working with the South African government to come to an agreement that would enable the local production of HIV prevention drug lenacapavir, World Health Organization partner Unitaid said Friday.

The government is working with global health organizations, including Unitaid and United States Pharmacopeia, to identify a South African pharmaceutical manufacturer that can produce the drug with quality assurance, Unitaid said.

A finalized agreement would allow the manufacturer to become the seventh firm licensed to produce lenacapavir for low- and middle-income countries, joining six other firms in Egypt, India, and Pakistan, Unitaid said.